We aim to transform protein production to allow universal access to biologics.
New state-of-the-art manufacturing facility
Inaugurated in September 2020 north of Madrid.
Single floor facility
Roughly 850m2 including administration, laboratory, rearing and production areas.
Production capacity
Around 1.7kg of recombinant protein/year, equivalent to antigen required to produce up to 100 million vaccine doses (dependent on protein and dose regiment)
GMP certification targeted H2 2021
AREAS OF FOCUS
Animal Health
20 years’ experience in the development and production of animal vaccines.
200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies.
FatrovaxRHD, first vaccine produced in CrisBio® received marketing authorization in the European Union and United Kingdom in Q3.
Learn more
Human Health
Building on experience in animal health, Algenex is expanding the production of proteins into human health to fully exploit the potential of its technology platforms
Learn more
Biocomponents
Algenex has an established track record as a producer of antigens proteins for the human and animal diagnostic and therapeutic markets and has also demonstrated the applicability of its technology platform CrisBio® to on-demand production of growth factors, enzymes and cytokines.
Learn more
LATEST NEWS
Company
Technology
La Agencia Española del Medicamento concede a Algenex la cer...
Learn more
Company
CrisBio
Algenex amplía su presencia en el mercado de la tecnología a...
Learn more
Company
Ofertas de trabajo en el Área de Calidad
Learn more